Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

PRADO, Cmm ; BEKAII-SAAB, T ; DOYLE, L. A ; SHRESTHA, S ; GHOSH, S ; BARACOS, V. E ; SAWYER, M. B

British journal of cancer, 2012-05, Vol.106 (10), p.1583-1586 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível